#ALNY (Alnylam Pharmaceuticals Inc.). Cursul de schimb și diagramele online.

#ACB Reveniți la lista instrumentelor #AMGN

Convertor valutar

292.06 USD
10 Jun 2026 21:59

$-0.03
(-0.01%)

Inchidere

$297.43

Deschiderea

$291.74

Petul maxim

$299.18

Pretul minim

$291.83

52-sapt. max.

$300.17

52-sapt. min.

$284.43

Descărcați arhiva

Deschideți graficul în ecran complet

Descărcați arhiva

Deschideți graficul în ecran complet

Alnylam Pharmaceuticals Inc. About company

Alnylam Pharmaceuticals Inc. is an American biopharmaceutical company, founded in 2002. The firm is mainly involved in the research and development of drugs for treating genetic disorders.

In 2016, Alnylam Pharmaceuticals Inc. was added to the Forbes list of the world’s 100 most innovative growth companies.

This year, the market capitalization of Alnylam Pharmaceuticals Inc. totals $17.65 billion. In 2021, it raised revenue of $844.29 million. In the first six months of 2022, the company earned as much as $224.82 million.

Alnylam Pharmaceuticals Inc.’s shares and factors shaping their value

The company has been listed on the NASDAQ exchange since 2004 under the ALNY ticker. Its share value currently totals $200-205. Over the past 12 months, ALNY has fluctuated in the range of $117 to $236.

When trading the firm’s stock, you should pay attention to the following factors:

The company has a heavy dependence on the state of the healthcare sector as a whole. Thus, new COVID outbreaks have a negative influence on its revenue growth;
The company occasionally introduces new drugs to the market, conducting clinical and laboratory trials and publishing the results beforehand;
Constantly growing revenues are the firm’s advantage;
Enough own funds to finance projects without the need to additionally issue securities.

InstaSpot – millions of clients trust us!Your choice speaks louder than words!

Keep fit and be successful like Oleg Taktarov!Bright start among InstaSpot brand ambassadors!

Convertor valutar

Alnylam Pharmaceuticals Inc. About company

Alnylam Pharmaceuticals Inc.’s shares and factors shaping their value